Core C: Genome Engineering Core
Core C: Genome Engineering Core
批准号:
10006187
负责人:
Bruce R Conklin
金额:
$28.35万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2024-08-31
关键词:
AdoptedAffectAntibiotic ResistanceAntibioticsBiological ProcessCRISPR interferenceCRISPR/Cas technologyCardiacCardiac MyocytesCardiac developmentCell LineCellsChromatinChromatin Remodeling FactorCicatrixClustered Regularly Interspaced Short Palindromic RepeatsComplexDNADNA DamageDNA MethylationDiseaseDistantEmerging TechnologiesEngineeringEnhancersEpigenetic ProcessEventGATA4 geneGene DeletionGene ExpressionGene Expression RegulationGene SilencingGenerationsGenesGeneticGenomeGenome engineeringGrowthHeart DiseasesHumanIndividualLaboratoriesLocationMediatingMethodsMethylationModificationMolecularMutationMutation DetectionNonhomologous DNA End JoiningNuclear Pore ComplexOpen Reading FramesPoint MutationProtein Complex SubunitProteinsRNA SplicingReagentRegulationResearch PersonnelResearch Project GrantsRoleServicesSingle base substitutionSiteTechniquesTechnologyTestingTransgenesUpdateValidationVariantYinbasecardiogenesischromatin modificationcombinatorialcongenital heart disorderdesigndigitalepigenome editingexperiencegenome editingimprovedinduced pluripotent stem cellinsertion/deletion mutationinterestknockout genemutantnew technologynovel strategiesnucleaseprotein complexprotein functionrepairedtooltranscription activator-like effector nucleases
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
CORE C – GENOME ENGINEERING CORE
Core C is focused on providing the most up-to-date genome engineering technology for studies of cardiac
development. We will develop and adopt emerging technology for CRISPR/Cas9-mediated gene deletions,
single-base changes, transgene insertions, and epigenetic remodeling. The PPG proposal utilizes advanced
genome engineering techniques. We will specifically provide genome engineering services of human iPSCs to
efficiently deliver engineered iPSCs for cardiac differentiation. The Genome Engineering Core will also
provide epigenome editing methods, that modify the cell's genome without cutting DNA. The CRISPR-
associated nuclease (Cas9) has been modified so that the nuclease is inactive in making “dCas” that can now
be used to carry and localize a wide variety of bioactive molecules to any location in the genome. We
pioneered the use of CRISPRi that silences gene expression in iPSCs, and are involved in developing better
methods that activate gene expression (CRISPRa).
Our team is an established leader in genome engineering, and has made efforts to improve every aspect of
genome editing in human iPSCs to benefit the PPG investigators in their efforts to unravel the molecular basis
of congenital heart disease. In the last 5 years, we made >50 different genetically modified human iPSC lines
with point mutations that exactly mimic the disease mutations, generate insertions/deletions (indels) for gene
knockouts, or introduce endogenous gene tags for molecular studies of protein function (Miyaoka et al., 2014,
Huebsch et al., 2015, Mandegar et al., 2016, Judge et al., 2017). The Genome Engineering Core will adopt
the latest methods for genome engineering, such as the use of CRISPR/Cas9 RNP-protein complexes (RNP)
to introduce insertion/deletions (indels), or delete discrete portions of genes to inactivate them in iPSCs as well
as in iPSC-derived cardiomyocytes, since RNP-mediated genome editing is more efficient and accurate in our
experience. In addition, the Genome Engineering Core will provide genome engineering services for the
insertion of transgenes at endogenous loci, as well as develop new CRISPR methods for the PPG
investigators to further investigate the cardiac interactome. The Genome Engineering Core will develop a
pipeline to deliver high-quality engineered iPSCs to the PPG projects with continuously updated techniques, to
answer vital questions in heart development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
-
批准号:10590420
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2021
-
负责人:Bruce R Conklin
-
依托单位:
C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches
-
批准号:10186371
-
项目类别:
-
资助金额:$212.63万
-
财政年份:2021
-
负责人:Bruce R Conklin
-
依托单位:
Core C: Genome Engineering Core
-
批准号:10245028
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2019
-
负责人:Bruce R Conklin
-
依托单位:
Core C: Genome Engineering Core
-
批准号:10471986
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2019
-
负责人:Bruce R Conklin
-
依托单位:
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
-
批准号:10455604
-
项目类别:
-
资助金额:$72.08万
-
财政年份:2018
-
负责人:Bruce R Conklin
-
依托单位:
Human microtissues for in situ detection and functional measurement of adverse consequences caused by genome editing
-
批准号:10249959
-
项目类别:
-
资助金额:$72.08万
-
财政年份:2018
-
负责人:Bruce R Conklin
-
依托单位:
JAX-Gladstone, SCGE Disease Models Studies Supplement
-
批准号:10620067
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2018
-
负责人:Bruce R Conklin
-
依托单位:
Therapeutic genome editing to treat Best disease
-
批准号:9980913
-
项目类别:
-
资助金额:$42.48万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs
-
批准号:9930312
-
项目类别:
-
资助金额:$4.41万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Protein quality control, cardiomyopathy, cardiotoxicity and human isogenic iPSCs
-
批准号:9384644
-
项目类别:
-
资助金额:$47.2万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Therapeutic genome editing to treat Best disease
-
批准号:10200060
-
项目类别:
-
资助金额:$41.21万
-
财政年份:2017
-
负责人:Bruce R Conklin
-
依托单位:
Identifying Therapeutic Targets for RNA Splicing-Related Cardiomyopathy
-
批准号:9195146
-
项目类别:
-
资助金额:$45.65万
-
财政年份:2015
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8138279
-
项目类别:
-
资助金额:$62.79万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8328586
-
项目类别:
-
资助金额:$61.65万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8532967
-
项目类别:
-
资助金额:$57.74万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Disease Specific Cardiac Tissue Models
-
批准号:8676918
-
项目类别:
-
资助金额:$60.54万
-
财政年份:2011
-
负责人:Bruce R Conklin
-
依托单位:
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)
-
批准号:8153362
-
项目类别:
-
资助金额:$23.86万
-
财政年份:2010
-
负责人:Bruce R Conklin
-
依托单位:
Tissue Engineering with a Modular RASSL Toolbox
-
批准号:7822201
-
项目类别:
-
资助金额:$2.62万
-
财政年份:2009
-
负责人:Bruce R Conklin
-
依托单位:
GenMAPP-CS, a dynamic resource pathway analysis
-
批准号:7904722
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2009
-
负责人:Bruce R Conklin
-
依托单位:
Cell Production Core
-
批准号:8590752
-
项目类别:
-
资助金额:$18.18万
-
财政年份:2008
-
负责人:Bruce R Conklin
-
依托单位:
海外基金